Qorvo Biotechnologies and Novel Biomarkers Catalyst Lab are developing prototype cartridge-based HCV cAg assays for confirmatory testing.
A tick-borne disease working group recommends the federal government explore using new technologies and repurposing existing ones to improve diagnosis.
The nucleic acid diagnostic platform they are developing doesn't require expensive optics, and it could be available as a manufacturing prototype in about a year.
Some researchers believe that the use of microfluidics in the analysis of exosomes will help clinicians overcome the problem of heterogeneity in cancer cells.
The POC assay is being developed under a DoD contract to detect pathogens that may pose a threat to national security and public health.
The measures are part of a long-term plan for the National Health Service that will be rolled out across the country to detect 3 out of every 4 cancers at an early stage.
The handheld device uses CMOS technology for multiplexed measurement of disease-linked metabolites and could prove useful for inexpensive POC testing.
Its platform is being developed for several medical conditions using separate modules to measure cells, proteins, nucleic acids, enzymes, and small molecules.
The researchers have built a benchtop breath test currently being validated, but a commercial test could be more than a decade away.
Since introducing new clinical platforms last year, Sciex has launched an automated sample prep system while Thermo Fisher has begun customer beta testing.